Biphosphonates in Metastatic Bone Disease of Neuroendocrine Neoplasms

#1862

Introduction: Metastatic bone disease (mBD) in patients with neuroendocrine neoplasms (NENs) is associated with a more aggressive behaviour

Aim(s): Their response to first line treatment with biphosphonates

Materials and methods: We studied 554 patients (259 females) with NEΝs: 94 gastric, 27 duodenal, 201 pancreatic, 70 small intestine, 42 appendiceal, 28 colic, 39 lung, 1 thymic, 32 unknown primary origin (UPO) and 16 elsewhere. Since September 2012 16 patients with NENs and mBD were recruited to receive 4mg of zoledronic acid monthly for 2 consecutive years; they were all followed-up by biochemical parameters and bone scan every 6 months

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Alexandraki K, Boutzios G, Nikolopoulos G, Tsoli M, Thomas D,

Keywords: bone disease,